» Articles » PMID: 30348610

Prevalence, Geographic Risk Factor, and Development of a Standardized Protocol for Fungal Isolation in Cystic Fibrosis: Results from the International Prospective Study "MFIP"

Citing Articles

Airway Mycobiota-Microbiota During Pulmonary Exacerbation of Cystic Fibrosis Patients: A Culture and Targeted Sequencing Study.

Angebault C, Vandenborght L, Bassinet L, Wizla N, Ferroni A, Dessein R Mycoses. 2025; 68(1):e70024.

PMID: 39816006 PMC: 11736540. DOI: 10.1111/myc.70024.


Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.

Milczewska J, Syunyaeva Z, Zabinska-Jaron A, Sands D, Thee S Eur Respir Rev. 2024; 33(174).

PMID: 39631927 PMC: 11615665. DOI: 10.1183/16000617.0068-2024.


The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis and -Positive Cultures.

Faerber J, Kawut S, Hadjiliadis D, Hong G Ann Am Thorac Soc. 2024; 22(2):193-199.

PMID: 39388639 PMC: 11808554. DOI: 10.1513/AnnalsATS.202312-1070OC.


Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.

Angebault C, Botterel F Mycopathologia. 2024; 189(5):82.

PMID: 39264513 PMC: 11392981. DOI: 10.1007/s11046-024-00887-6.


Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.

Saiman L, Waters V, LiPuma J, Hoffman L, Alby K, Zhang S Clin Microbiol Rev. 2024; 37(3):e0021521.

PMID: 39158301 PMC: 11391703. DOI: 10.1128/cmr.00215-21.